Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smart monitor improve blood sugar control for dialysis patients?

NCT ID NCT06641765

Disease control Sponsor: Bo Feldt-Rasmussen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a continuous glucose monitor (CGM) helps dialysis patients with type 1 or type 2 diabetes control their blood sugar better than standard finger-prick tests. 96 participants will be split into three groups: standard care, intermittent CGM use, or continuous CGM use for 9 months. The goal is to see if CGM increases the time blood sugar stays in a healthy range.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous Glucose Monitor (Dexcom G7)
What this could lead to
If successful, this could show that CGM helps dialysis patients better manage their blood sugar and reduce complications.
What could go wrong
This is a relatively small, early-stage study (96 participants) and may not prove long-term benefits. The device may not be accurate or practical for all dialysis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

96 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained before any trial-related procedures are performed * Diabetes, one of the following groups: Type 1 diabetes OR Type 2 diabetes receiving glucose-lowering therapy OR Type 2 diabetes managed with lifestyle changes with an HbA1c ≥ 50 mmol/mol * Maintenance haemodialysis or peritoneal dialysis (minimum of two weeks) * Subject must be willing and able to comply with trial protocol and be fluent in Danish or English Exclusion Criteria: * Major allergy to tape/adhesives * Women who are pregnant or planning pregnancy * Ongoing use of CGM * Ongoing use of insulin pump

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypoglycemia type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Diabetes mellitus type 2 Diabetes mellitus, type 1 Haemodialysis Peritoneal dialysis

Contacts and locations

Locations

  • Herlev Hospital

    Herlev, 2730, Denmark

  • Holbæk Sygehus

    Holbæk, 4300, Denmark

  • North Zealand Hospital, Hillerød

    Hillerød, 3400, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Zealand University Hospital

    Roskilde, 4000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.